Betamethasone

證據等級: L5

預測適應症: 10 個

Betamethasone: From Inflammatory & Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Betamethasone is a potent synthetic glucocorticoid corticosteroid widely used in clinical practice for a broad range of inflammatory, allergic, and autoimmune conditions; no India (CDSCO) regulatory registration records were found in this dataset. The TxGNN model predicts it may be effective for Alopecia Areata, with 7 clinical trials and 20 publications currently supporting this direction. Evidence includes a 2023 Cochrane systematic review and multiple completed randomised controlled trials.

Quick Overview

Item	Content
Original Indication	No India (CDSCO) registry record available; betamethasone is a glucocorticoid corticosteroid broadly used for inflammatory and autoimmune conditions
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.97%
Evidence Level	L2 (1 completed Phase 2 RCT + multiple completed Phase 4 RCTs + Cochrane review)
India Market Status	Not Marketed (no CDSCO registrations found)
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Betamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive activity. Although detailed MOA data is unavailable in this Evidence Pack, it is well-established that betamethasone binds to intracellular glucocorticoid receptors, suppresses the transcription of pro-inflammatory cytokines (including IL-1, IL-6, TNF-α), and inhibits T-lymphocyte activation and proliferation.

Alopecia areata (AA) is a tissue-specific autoimmune disorder in which autoreactive CD8⁺ T cells breach the immune privilege of hair follicles and trigger non-scarring hair loss. This immune-mediated mechanism is precisely the pathological pathway that corticosteroids are designed to suppress. The mechanistic match between betamethasone’s immunosuppressive action and the T-cell-driven pathology of AA is therefore direct and biologically coherent.

In clinical practice, corticosteroids — administered topically, intralesionally, or systemically as pulse/mini-pulse regimens — are already regarded as first- or second-line agents for AA. The TxGNN prediction is therefore consistent with existing clinical knowledge, and the strength of the supporting evidence (including a Cochrane review and multiple RCTs comparing betamethasone formulations head-to-head with other agents) strongly reinforces its plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06786689	Phase 2	Completed	60	Compared weekly azathioprine pulse vs. betamethasone oral mini-pulse (BOMP) in moderate-to-severe AA; directly evaluates betamethasone as primary intervention
NCT03535233	Phase 4	Completed	40	Combined topical 5% minoxidil + potent topical corticosteroid vs. intralesional triamcinolone in AA; RCT assessing topical corticosteroid combination efficacy
NCT02350023	Phase 4	Completed	50	Head-to-head comparison of topical betamethasone vs. topical latanoprost for localised AA; provides direct comparative evidence
NCT05803070	N/A	Unknown	59	Topical cetirizine 1% vs. topical betamethasone valerate 0.1% in localised AA; efficacy and safety comparison
NCT06087796	Phase 1	Unknown	60	Topical pentoxifylline 2% gel and topical metformin 10% gel vs. topical betamethasone valerate 0.1% cream in patchy AA; novel comparator study
NCT04207931	Phase 4	Recruiting	250	Multicentre prospective study of treatment outcomes in Central Centrifugal Cicatricial Alopecia (related scarring alopecia subtype); corticosteroid arm included
NCT01111981	Phase 4	Unknown	30	Safety and efficacy of clobetasol propionate 0.05% foam in Central Centrifugal Cicatricial Alopecia; related corticosteroid comparator

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37870096	2023	Cochrane Systematic Review	Cochrane Database of Systematic Reviews	Network meta-analysis of all AA treatments; establishes comparative evidence base for corticosteroids including betamethasone
34400956	2021	RCT	Iranian Journal of Pharmaceutical Research	Double-blind, placebo-controlled RCT (n=36) comparing oral betamethasone pulse, methotrexate, and combination in severe AA; betamethasone arm showed significant hair regrowth
40510104	2025	RCT	Cureus	Randomised controlled trial (n=60) comparing oral cyclosporine vs. betamethasone mini-pulse in AA; provides head-to-head comparative efficacy data
36257912	2022	RCT	Dermatologic Therapy	Blinded multi-group RCT evaluating latanoprost vs. minoxidil, betamethasone, and combinations in AA (6 groups, n=18 each); comprehensive comparative design
39393548	2025	RCT	Journal of the American Academy of Dermatology	Randomised controlled trial of microneedle transdermal delivery of compound betamethasone in AA; demonstrates novel delivery approach reduces injection pain while maintaining efficacy
38623137	2024	RCT	Cureus	Comparison of topical betamethasone dipropionate vs. topical minoxidil in AA patients; direct head-to-head RCT
40519428	2025	Observational Study	Cureus	Prospective study assessing efficacy, safety, and outcomes of oral betamethasone mini-pulses in moderate-to-severe AA
37992355	2023	Review	Dermatology Practical & Conceptual	Comprehensive review of corticosteroid pulse therapy in AA: efficacy, relapse rates, side effects, and prognostic factors
36461625	2023	Review	Pediatric Dermatology	Review of pulse dose corticosteroid therapy dosing and administration specifically in paediatric AA; summarises available dosing regimens
32594786	2022	RCT	Journal of Dermatological Treatment	Within-patient randomised controlled trial comparing intralesional betamethasone vs. triamcinolone acetonide in localised AA; directly evaluates betamethasone intralesional efficacy

Safety Considerations

Drug Interactions (451 total interactions identified):

Severity	Interacting Drug	Clinical Relevance
Major	Adalimumab	Concurrent use significantly increases infection risk due to compounded immunosuppression
Moderate	Ibuprofen, Ketorolac	Increased risk of gastrointestinal ulceration and bleeding with concomitant NSAIDs
Moderate	Acarbose, Albiglutide	Glucocorticoids antagonise hypoglycaemic effects; blood glucose monitoring required
Moderate	Acetazolamide	Risk of hypokalaemia may be increased
Moderate	Nifedipine	Possible pharmacokinetic interaction; blood pressure monitoring warranted
Moderate	Ethinylestradiol	Oestrogens may increase corticosteroid plasma levels
Moderate	Fluvoxamine	CYP3A4 inhibition may increase betamethasone exposure
Moderate	Fosamprenavir	CYP3A4-mediated interaction; monitor for increased corticosteroid effects
Moderate	Isotretinoin	Concurrent use increases risk of raised intracranial pressure
Moderate	Immunologicals (Adalimumab, Alefacept, Alemtuzumab, Aldesleukin, Tetanus toxoid)	Betamethasone may reduce immune response to vaccines and biologics
Minor	Formoterol, Salbutamol	Hypokalaemia risk may be mildly increased

Note: Detailed key warnings and contraindications from the package insert are not available in this Evidence Pack. Please refer to the full prescribing information before clinical use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Betamethasone is a mechanistically well-justified treatment for alopecia areata — an autoimmune disease driven by T-cell activity that is directly suppressed by glucocorticoids — and is already used in clinical practice for this indication globally, supported by a 2023 Cochrane systematic review, multiple completed RCTs, and ongoing comparative trials. However, no India (CDSCO) regulatory registration was found in this dataset, formal large-scale Phase 3 RCT data is absent, and safety details (key warnings, contraindications) are not available in this pack.

To proceed, the following is needed:

Regulatory verification: Confirm actual CDSCO registration status in India, as betamethasone products are widely sold; the current dataset result (0 registrations) may reflect a data gap rather than true market absence
Package insert review: Obtain and review the full India package insert for key warnings and contraindications (DG001 — currently blocking S1 safety assessment)
MOA documentation: Retrieve mechanism of action data from DrugBank (DG002) to complete the mechanistic evidence dossier
Route-specific assessment: Determine which administration route (topical, intralesional, oral mini-pulse) is most appropriate for the India clinical context and patient population
Paediatric vs. adult dosing plan: Given existing evidence for both adult and paediatric AA, a dose-stratified safety monitoring plan should be developed
DDI screening: For AA patients commonly co-prescribed immunosuppressants or biologics (e.g., adalimumab — a major interaction), prospective DDI screening protocols should be established before clinical deployment

⚠️ This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.